The most commo n clin ical syndro mes that cause nasal congestion are allergic rhinitis, vasomotorrhinitis, chronic sinusitis, and upp er respiratory vira l inf ections (common colds) . Nasa l congestion, in turn , can lead to sequelae suc h as sinusitis, otitis media, and the onse t or worsening of mild to severe sleep dis turbances, including obs tructive sleep apnea. There is a host of conservative treatments, inc lud ing decongestan t pharmacotherapy, antiallergy measu res, and nasal dilation dev ices. Several surgical procedu res are also available. This art icle reviews the current guidelinesfor the workup and diagnosis of nasa l congestion and briefly describes the many and var ied approaches to treatment. Research support for this article was provided by Schering Corp. 690 disorders, such as recurrent rhino sinu sit is, otitis medi a, bronchit is, and asthma. Furth er adding to the condition ' s eco nomic imp act are less tangibl e factors, such as absenteeism and decreased producti vity.'
Introduction
Nasal co nges tion is a key component of rhinitis. Rhinitis is defin ed as an infl amm ation of the lining ofthe nose that is characterized by nasal congestion, rhinorrhea , sneezing, and/or itching. ' Nasal congestion cau ses nasal obstruction, but not all nasal obstru ction is caused by congestion . Nasal con gestion involves the cavernous tissues in the turbinates. Th e focus of this artiele is on the phenomenon of nasal congestion rather than on the broader problem of nasal obstruction. Nasal ob struction was reviewe d by Kim melma n, who in 1989 published a practical outline to guide the treatment of the most co mmon etiologies, including allergic rhinitis, infectious rhinitis, and vaso motor rhinitis.' Kimmelman estimated that in the United States alone at that time, an estimated $5 billi on was bein g spent annually on med ications to relieve nasal obst ruc tion. An additional $60 mill ion was being spent on surg ical reme dies, and another $ 10 billion on the treatment of associated RinoFlow is different than anything your patients have tried before. It provides a gentle aerosol mist that soothes and deanses naturally, without drugs. And it offers two therapy settings: Phase One washes, hydrates and drains the nasal cavity; Phase Two promotes drainage of the sinuses providing an added level of relief. RinoFlow will complement your medical management of ehronic sinusitis and rhinitis sufferers.
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Pregnaney must be ruled out. The estrogen that is produeed during pregnancy tends to inhibit acety lcholinesteraseaetivity, leading to edema of the nasa l mueosa and resultant congestion. ' Physicalexamination. The physical exam ination should begin during the interview. The physician should determinethe presenee or absence of hyponasal speeeh, which suggests that sinus and nasa l eongestion is fairly severe. During the interview, one mig ht also deteet signs of alIergy, such as "allergic shiners" (periorbital edema), the "allergic salute," and urticaria. AIthough the exam ination shouldconcentrate on the nose, it should also encompass the entire head and neck. A complete head and neck examination should always be performed, and note shou ld be taken of any changes in the eyes , eyelids, ears, and throat.Such changes can include the presence of chemosis, epiphora, middle ear effusion, inflammation in the pharynx, and lymphadenopathy.
The presence of wheezing might indieate concomitant asthma. Ideally, the nose should be examined before and after deeongestion via anterior rhi noscopy. Sometimes a mare detailed examination of the turbinates, meatus, septum. and nasopharynx by rigid and/or flexib le endoseopy is required.
Measurement ofnasal resis tance . Since the early 20th eentury, researchers have tried to measure nasal resistance and nasal patency. Initially, a simple mirror was plaeed under the nostri ls to de teet airflow. In time, rhinomanometric techniques evolved that simultaneously measured pressure and flow . Caleulations of transnasal resistanee were made according to Ohm's law.
In reeent years, we have seen the development of aeoustie rhinometry, which makes use of reflected sound wavesto estimate nasal geometry and area. Thi s method has great clinical potential because it is noninvasive, rapid, and performed quite eas ily." Several centers have shown that acoustic rhinometry can quantify the effect of septoplasty and the medical trea tment of nasal polyposis. Aeoustie rhinometry has also been used to examine patients before and afte r functional endoscopic sinus surgery in order to measure the size of the surgically produeed eavity .7,8 Porter et al reported on the use of manometrie rhinometry .9 In this procedure, avolume of air tha t has beenremovedfrom a closed nasal space is measured, and thepressure change in the cavity is recorded. The original volume is then caleulated by mea suring the change in pressure.
All these method s have been useful from aresearch perspeetive, and aco ustic rhinometry is gaining popularity as a clinical tool as weIl.
Other metlzods of evaluation . Various laboratory ex-692 aminations and radiologic studies can aid in identifying the cause of congestion and in estimating its extent. Laboratory tests include measurements of the complete blood cou nt with differential, the erythrocyte sedimentation rate, and serum total and allergen-specific immunoglobu lin E levels as weIl as analyses of nasal cyto logy and aIlergic skin reactions . Radiologic studies can also provi de useful information. Computed tomography (CT) of the sinuses provides a good disti nction between bone and soft tissue, and magnetic resonance imaging differentiates soft tissue masses.
Common differen tial diagnoses
Among the differentia l diag noses for patients with nasal congestion are rhinitis, structura l defects, neoplasms, drug reactions, endocrine or metabolic conditions, and systemic inflammatory and granulomatous conditions (tab le 1).
Rhinitis.
AIlergic rhinitis might be the most common cause of nasal congestion. Patients are typicaIly young, otherwise hea Ithy adu lts who have a history of sneezing and itchy and runny nose and eyes, wit h or without previous nasa l congestion. Patients whose rhini tis is per- Young children experience an average of six to eight colds a year. The associated rhinorrhea is usually copious . Viral rhinitis (colds) normally resolves spontaneously within 7 days, while bacterial rhinosinusitis persists longer and features more intense symptoms . Endoscopy to visualize the nasal cavity, including the ostiomeatal unit, helps make the diagnosis. Under endoscopic guidance, any purulent material seen can be sampled and cultured to direet antibiotic therapy. 10 CT of the sinuses can assist in the evaluation of chronic disease.
Structural causes. The most common structural abnormality is a deviated nasal septum, which can cause a sensation of chronic unilateral nasal congestion or congestion that fluctuates with the nasal cycle . The patient might report a history of nasal trauma. The physical examination usually reveals an anterior septal deflection. The turbinates can exhibit a compensatory hypertrophy on the side away from the deviation. Nasal valve disorders can also cause nasal obstruction.
Lesional causes. Obstruction and congestion can be caused by idiopathic nasal or nasopharyngeal polyps or polyps that occur in association with cystic fibrosis, asthma, aspirin sensitivity, chronic rhinosinusitis, and allergic rhinitis. Nasal polyps appear as bluish, waterfilled "bags." Other neoplasms that can appear in the nose are angiofibromas, adenocarcinomas, melanomas, esthesioneuroblastomas, and neuroendocrine carcinomas.
Drug-induced causes. Rhinitis medicamentosa is the most commonly recognized type of drug-induced congestion. It is a rebound congestion that is caused by the overuse of topieal nasal decongestants. Other common drugs that can provoke similar symptoms are aspirin, nonsteroidal anti-inflammatory drugs, beta blockers (oral and ophthalmic), bromocriptine, estrogens, oral contraceptives, prazosin, methyldopa, phentolamine, guanethidine, reserpine, and tricyclic antidepressants.' There seems to be no correlation between the severity of rhinitis medicamentosa and the frequency of topieal decongestant use. 12 • 14 Some studies have shown that in addition to the vasoconstrictor in decongestants, the preservative Volume 79, Number 9 (usually benzalkonium) might also contribute to, and even accentuate, rhinitis medicamentosa."
Endocrine and tnetabolic causes. States of hormonai flux (e.g., pregnancy and puberty) are associated with nasal mucosal engorgement and obstruction. The presence of hypothyroidism might also be related to rhinitic symptoms.
Systemic inflammatory and granulomatous causes. Vasomotor and idiopathic rhinitis are relatively common forms of rhinitis and are characterized by symptoms of nasal obstruction, postnasal drainage, anterior rhinorrhea, and sneezing ofunknown etiology. Symptoms manifest in response to environmental triggers, such as smoke, dust, fumes, exhaust, changes in temperature and humidity, and strong perfumes, bleaches, and solvents. It is neeessary to exclude othercauses of rhinitis before a patient' s condition can be diagnosed as idiopathic rhinitis.
The symptoms of nonallergic rhinitis with eosinophilia syndrome (NARES) are similar to those of perennial allergic rhinitis-sneezing, itching, rhinorrhea, and nasal congestion. Allergy tests are negative, but nasal smears are positive for eosinophils. NARES might represent an allergy to an unknown agent or an overlap syndrome with vasomotor rhinitis, in which eosinophilia is absent. ' Symptoms can also be caused by numerous uncommon inflammatory conditions, including sarcoidosis, Wegener's granulomatosis, Churg-Strauss syndrome, lupus, other collagen diseases, and Sjögren's syndrome. Rhinitis is just one part of a constellation of systemic symptoms in these cases .
Nasal obstruction and sleep disturbance
The part that nasal obstruction plays in sleep disturbance is controversial. Some authors believe nasal obstruction can cause frank obstructive sleep apnea syndrome, while others minimize its role .
In the norrnai awake state, nasal airway resistance markedly exceeds that of oral airway resistance. During sleep, the relaxation of the oral and pharyngeal musculature leads to a reversal of the resistance patterns of the nose and oral cavity, and oral airway resistance increases. Breathing through an inefficient oral cavity requires increased effart, which leads to greater negative pressures in the pharynx and a higher risk of collapse. The resistance in the nasal cavity, which has a mare rigid frame, is more constant during both the awake and asleep states. The pharynx still connects the nose to the trachea, but the lower resistance to airflow makes a collapse of the pharynx less !ikely. The nose appears to be the more efficient route of breathing during sleep."
Although the effects of sleep on the nose are less than its effects on the oral cavity , changes in nasal patency do occur. Nasal resistance is known to increase during recumbency, as mucosal congestion takes place.'? An un-Only Augment n is recommende as primary therapy for all acute bacterial rhinosinusitis (ABRS) patient types· Eaehdose should be takenwith a meal or snaek to reduee the possibility 01gastrointestinal upset. Manyantibiotieseaneause diarrhea. It diarrhea is severe or lasts mor e than 2 or 3 days. eall your doctor. Be sure your ehild eompletes theenti,e preseribed eourse 01 t,eatment. even il he/she begins to leeI bener afte, a few days. Keep suspension relrige,ated. Shake weil belore using. When dosing a ehiIdwith Augmentin suspension (Iiquidl . use a dosing spoon 0' medieine dropper. Rinse the spoon or droppe, alter eaeh use. Bottles of Augmentin suspension may eontain more liquid than required. Follow your doetor's instruetionsabout theamount to use and thedays of treatment your child requires. Discard any unusedmedicineo Phenylkatonuries: Eaeh 200 mg Augmentinehewable tablet eontains 2.1 mg phenylalanine; eaeh 400 mg ehewabletableteontains4.2mg phenylalanine: eaeh 5 mLof eithe, the200 mg/5 mLor 400mg/5 mL oralsuspensioneontains7 mgphenylalanine_OtherAugment inproduetsdonot eontainphenylalanineand can be usedbyphenylketonuries. Contaetyour physieian 0' pharmaeisl. Orug Interactions: Probenecid dee reases therenal tubularsecretian of amoxieillin. Concurrent usewith Augmentin may result in inereased andprolongedblood levels 01amoxieillin. Co ·administrat ion of probenecid eannot be recommended. The coneurrent admi nistrati on of allopurinol and ampicillin increases substantiallytheinci denee of rashes in pat ients reeeivingboth drugs ascomparedto pat ients reeeiving ampicillinalone. It is not known whetherthispotentiationof ampicillin rashes is due to altopurinol orthe hyperurieemia present in these pat ients. There arenodata with Augmentinand allopurinol administered concurrently.
In common with other braad·speetrumanti biotics, Augmentinmayreduce theefficacy of oral eontraeeptives.
Orug/laboratory Test Interactiens:Oral administrationof Augmentin will result in highurine concentrations ofamoxicillin. Highurineconeentrat ions ofampieillin mayresult in false-positivereaetionswhen tesllng lor the presenee of glueose in urine usingClinitest3. Benedief s Solut ion 0' Fehling's Solution.
Si nce this effeet may alsooecurwith amoxieillin and therefore Augmentin. it is reeommended that glucose tests based on enzyrnatic glucoseoxidasereaetions(such asC l i n i st i x~orTes-Tape 31 beused. Following administration of ampieillin to pregnant women a transi ent deerease in plasma concentration 01 total eonjugated estriol. estriol·glueu, onide. eonjugated estrone and estradiol has been noted. This eUee t may also occur with amoxicillin and therefore Augmentin. derlying limitation of nasal airflow, which can be subelinical during the daytime while the patient is upright, can manifest at night shortly after the patient becomes reeumbent. Any process that produces nasal congestion while the patient is awake will have an additive effect on nasal airflow during sleep.
Studies have demonstrated a significant correlation between nasal resistance and snoring.":" Patients who snore habitually are more likely to complain of nighttime nasal congestion, nasal discharge, and congestion caused by allergic rhinitis.
Upper airway resistance syndrome (UARS) is characterized by an increase in the amount of work that is required to breathe during sleep in order to overcome the elevated airway resistance , UARS causes numerous microarousals that fragment sleep and diminish its quality. Sleep fragmentation has been shown to lower patients' subjective assessments ofwakefulness, mood, and attention.'? Patients with UARS often complain of daytime somnolence, which can be assessed objectively with instruments such as the multiple sleep latency test.
It appears that the nose might play a significant role in the development of UARS. The nasal obstruction associated with allergic rhinitis has been found to fragment sleep and significantly increase the incidenee of microarousals." The effects of allergic rhinitis can be alleviated with medical therapy to reduce allergic inflammation . Intranasai topieal corticosteroids significantly reduce nasal congestion in patients with allergic rhinitis, which improves the quality of their sleep and alleviates daytime sleepiness."
Patients with UARS do not have frequent enough apneic episodes to meet the criteria for obstructive sleep apnea syndrome (OSAS), Some authors believe that UARS might be a precursor to OSAS and suggest that a continuum exists between normal nocturnal breathing, occasionai snoring, habitual snoring, UARS, and OSAS. For example, patients might progress from one point to another on the continuum as their weight fluctuates. Similarly, nasal obstruction might move a patient up or down the continuum.
Adireet linear correlation between nasal resistance and the respiratory disturbance index (RDI) has not been observed, although the two indiees do seem to have an association. 16 ,1 8Complete obstruction from nasal paeking has long been suspected of causing apneic episodes. Studies that provide evidence both for and against packing as a cause of OSAS have been published.P:" It might be that patients who undergo nasal paeking in addition to having other risk factors make up the primary population of those who experience apneic episodes."
Patients who are allergic to ragweed have longer and more frequent episodes of obstructive apnea during their acute season than they do during their off season, which 696 might be attributable to increased nasal resistance." Fixed anatomic obstructions, such as a deviated nasal septum, might contribute to OSAS. Surgical repair can improve the RDF8Nasal obstruction can be at least partly responsible for the development of OSAS.
Conservative management
Effective conservative treatments inelude decongestant drugs, antiallergy measures, and nasal dilation devices (table 2) .
Decongestants. Decongestants generally serve as the first-line treatment for nasal congestion (table 3) . They are marketed as topieal and oral formulations.
Topieal. Topieal vasoconstrictors are divided into two categories : the sympathomimetic amines and their imidazoline derivatives. The sympathomimetic amines inelude ephedrine and phenylephrine, and the imidazolines inelude naphazoline, oxymetazoline, tetrahydrozoline, and xylometazoline. Both categories of drugs produce local vasoconstriction by stimulating the adrenergic receptors on the lamina propria ofvessels. The imidazolines have a lesser myocardial and bronchiolar effect, whereas the amines produce more rapid tachyphylaxis and are less toxic to the nasal cilia, Patients who experience rhinitis medicamentosa can be treated by slowly weaning them from the topieal agent. The patient should be informed that congestion might last for as long as 2 to 4 weeks after their medieation is stopped. Sleeping with the open nostril upward can help alleviate the congestion. The addition of steroids can be helpful in more difficult cases."
Oral. The oral decongestants ephedrine, pseudoephedrine, and phenylpropanolamine all have alphaadrenoceptor agonist activity. Ephedrine also has an effect on beta-adrenoceptors. Alpha-adrenergic vasoconstrictors diminish nasal obstruction, but they have no influence on itching, sneezing, and nasal secretion.' All deeongestants ean interaet adversely with monoamine oxidase inhibitors (MAOIs), tricyclie antidepressants, indomethaein, beta bloekers, methyldopa, some general anestheties, digitalis, antihypertensives, rauwolfia alkaloids, othereentral nervous system (CNS) stimulants, and possibly theophylline. Possible side effeets include restlessness, nervousness, insomnia, headaehe, angina peetoris, taehyeardia, and hypertension. Beeause deeongestants produee generalized peripheral vasoeonstrietion, they must be used eautiously at all times and should be avoided by patients who have eardiovaseular disease, hypertension, diabetes mellitus, glaueoma, thyroid disease, hepatic disease, renal disease, peptie ulcer, and possibly duodenal ulcers. Deeongestants ean also preeipitate urinary retention in patients with prostatic hypertrophy."
Antiallergy measures. For patients who have allergie causes of nasal eongestion, there are two general treatment options: (1) avoidanee and environmental eontrol and (2) pharmaeotherapy with antihistamines, antihista- Table 4 . Antihistamines
First generation
Chlorpheniramine Diphenhydramine Hydroxyzine Triprolidine
Second generation
Acrivastine Cetirizine Fexofenadine Loratadine
Topieal Azelastine (nasal) Levocabastine (ophthalmic) Olopatadine (ophthalmic) 698 mine/deeongestant eombinations, eortieosteroids, mast eelI stabilizers, and immunotherapy. These modalities ean be used singly or in eombination, depending on the severity of the disease.
Avoidanee and environmental contro!. Avoidanee is a mainstay of allergy treat ment. Indoor and outdoor allergens must be identified and avoided. The most common allergens are pollen (seasonal allergic rhinitis), house dust mites, animal dander, and molds (perennial allergie rhinitis).
Antihistamines. H 1 antihistamines represent one of the basic treatment options for allergic rhinitis (table 4) . Their primary aetivity involves adose-related competitive binding of the H 1 reeeptors on target eelIs.
The first-generation, or "classic," antihistamines are ehlorpheniramine, diphenhydramine, hydroxyzine, and triprolidine. These drugs are lipophilic and thus cross the blood-brain barrier and attach to H 1 reeeptors on brain eelIs. Therefore, they typieally eause sedation. They ean also have antieholinergie effeets, such as mucous membrane dryness , eardiae stimulation, blurred vision, deereased gastrointestinal motility, and urinary retention. The elassie antihistamines ean inerease the CNS-depressant effeets of various other drugs , such as MAOIs, trieyclie antidepressants, alcohol, antiparkinson drugs, barbiturates, tranquilizers, and narcotics ."
The second-generation antihistamines include aerivastine, eetirizine, fexofenadine, and loratadine. Fexofenadine and loratadine are nonsedating agents, and aerivastine and eetirizine have low sedative properties." There have been reports that patients who used astemizole and terfenadine (both ofwhieh have been withdrawn from the U.S. market) experieneed serious cardiac side effeets (torsade de pointes) when these drugs were taken with a maerolide antibiotie of an imidazole antifungal, as well as when take n in overdose. Cetirizine, fexofenadine, and loratadine do not eause these drug interaetions, nor do they produee torsade de pointes, even at high doses; extensive data on aerivastine are not yet available, but it appears to lack this effeet also.
Three of the newer antihistamines available for topieal use are azelastine, levoeabastine, and olopatadine. Azelastine inhibits the produetion ofhistamine and other inflammatory mediators and seems to demonstrate deeongestant properties. It is mildly sedating and ean eause a dose-related taste alteration. Although an oral form is available elsewhere, this drug is available only as a topieal nasal agent in the United States. Levoeabastine is applied topieally to the eyes . It is highly seleetive and has a very rapid onset of action and prolonged aetivity. Levoeabastine appears to produee no sedati ve or psyehomotor alterations ."
Antihistamine/decongestant combinations. Combined antihistamine/deeongestant preparations are prevalent in the market ( It performs strohovideolaryngoscopy at the touch of a hutton. congestion but contral rhinorrhea, sneezing, tearing , and nasal and ocular itching . The entire symptom complex is often present in allergic rhinitis. Many studies have shown that the two elasses of drugs are mare effective in combination than either individual agent pIus placebo." :"
Cortieosteroids. Steraids reduce inflammation by decreasing the infiltration of inflammatory cells , especially mast cells and eosinophils. They also diminish the hyperreactivit y and vascular permeability of the nasal mucosa, and they might decrease the release of mediators fram mast cells.' Steraids can be taken orally , parenterally, topically, and, by some , intramuscularly. For nasal congestion , topieal nasal administration is preferred because it enhances the drug ' s therapeutic value while minimizing its systemic effects (table 6). Hilberg showed that the topieal stera id budesonide was superior to the antihistamine terfenadine in relieving nasal congestion, although this might not be a good camparisan because terfenadine would not be expected to decrease conge stion ." The steraid fluticasone has been shown to be significantly mare effective than the antihistamine loratadine in treating seasonal allergic rhinitis." Other topieal steroids inelude beelomethasone , flunisolide , mometasane, and triamcinolone.
The impraper use of topieal steraids can cause local burning and irritation, candidiasis, and septal perforations. Their raIe in inducing glaucoma, cataracts, and grawth suppres sian in children has been hotly debated, although most studies suggest that topieal intrana sal (as opposed to orall y inhaled ) steraids do not increase the incidenee of these side effects.
Barnes and Pedersen, in their exten sive review, concluded that the dose of inhaled steroid s that is used for asthma is safe for most adults and children." These doses are similar to or greater than the doses used for chranic rhinitis .
Mast eel! stabilizers. Cromolyn and the mare patent nedocramil prevent the dissolution of the mast cell wall and thereby prevent degranulation. They inhibit the ealcium-dependent degranulation that occur s with the accumulation of cyelic AMP. As aresult, these agents reduce nasal itching, sneezing, rhinorrhea, and nasal obstruction in allergic rhinitis. Both cramolyn and nedocramil can be used topically with minim aI side effects. However, because their duration of effect is quite short, they must be applied several times a day." Cramolyn is available as an OTC praduct in the United States ; nedocramil is not yet available in topie al nasal form. Cramolyn has been shown to be less effective than nasal steroids in contralling allergic symptorns."
Itnmunotherapy. Immunotherapy (desensitization) is not necessary for all allergic patient s. It is usually considered only for patient s with moderate to severe symptoms who have experienced insufficient allergy contral with 700 Table 5 . Antihistamine/deeongestant eombinations Acrivastine and pseudoephedrine Azatadine and pseudoephedrine Brompheniramine and phenylpropanolamine Chlorpheniramine and phenylpropanolamine Cinnarizine and phenylpropanolamine Fexofenadine and pseudoephedrine Loratadine and pseudoephedrine Triprolidine and pseudoephedrine pharmacotherapy and avoidanee techniques. Although the exact mechani sms of immunotherapy are not completely understood, we do know that they involve the development of immunoglobulin G-blocking antibodies and the alteratian of T cell interactions ."
Anticholinergics, such as ipratropium and oxitrapium, decrease the amount ofnasal secretions, but they have no effect on nasal obstruction. Anticholinergics inhibit muscarinic cholinergic receptors. They have no raIe in treating nasal conge stion. "
Nasal dilation devices. External nasal dilators (e.g., Breathe Right nasal strips) have been reported to imprave breathing for patients with anterior nasal obstruction as weIl as for pregnant women. They have even been reported to reduce the number of obstructive respiratory events in infants. These devices decrease upper airway resistance by enlarging the area in the nasal valve." Another helpful tool is the nasal continuous positiveairway pressure (CPAP) device, which exerts a pneumatic splinting effe ct." It works primarily on the elastic upper airway, preventing airway collapse and eliminating snoring and its elinical complications.
Surgical management
Among the many surgical procedures that have been used for the treatment of nasal obstruction are the trimming of the inferior turbinates, laser therapy, linear cautery , submucosal diathermy, and turbinate cryotherapy. All of them have been reported to be effective over the short term, but they provide no sustaine d benefit.? Radiofrequency ablation (somnoplasty) and micradebridement of the turbinates are two of the newer tech- 
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